Menu

ABOUT US

IT’S TIME TO HEAL

Numinus exists to help the world heal, starting with addressing the global crisis in mental health by harnessing the power and promise of psychedelic medicine. Through our integrated model, we are actively contributing to the body of primary and clinical psychedelic research while delivering best-in-class therapeutic protocols across our clinics.

Going beyond breakthroughs

We understand that psychedelics are powerful medicines, but not magic pills. We understand that they can profoundly change lives, families, and communities, and that success requires more than just a breakthrough experience—it also takes careful, sensitive attention to every individual’s story, mindful preparation, and a grounded, realistic plan for what comes after.

Multidisciplinary expertise with human-centred care

Numinus boasts a diverse and interdisciplinary team of professionals, from physicians and psychiatrists to mindfulness teachers, nurses and psychotherapists, researchers and technicians. Our protocols are backed by rigorous science, and delivered by a team that understands that even the best tools still require genuine human care to be effective.

Curiosity and humility

At the core of what we do at Numinus is a deep sense of curiosity and humility about everything we encounter. We know that psychedelics, mindfulness, and embodied practices are not new tools, but rather owe a debt to some very old ways of being and caring for one another. We’re working every day to honour that wisdom and those traditions, and integrating it with the best that modern science has to offer.

OUR CLINICal TEAM

View All Members

RECENT COMPANY UPDATES

News
8 MIN READ
Dr. Reid Robison Interviewed by Daily Hive
In an interview with The Daily Hive, Dr. Reid Robison, Chief Clinical Officer at Numinus, discusses the potential benefits of psychedelic-assisted therapy for treating conditions such as depression, anxiety, and […]
January 9, 2023
News
What Are the Benefits of Microdosing? | Goop
Numinus's VP of Psychedelic Neurology, Dr. Evan Lewis, chats with  Kelly Martin from Goop to discuss microdosing’s current research findings and the potential for it to be a treatment in neurological disorders.
August 12, 2022
News
Meet Payton Nyquvest | Psychedelia Magazine
Our CEO Payton Nyquvest goes in depth with Tom Zuber in the 2021 winter edition of Psychedelia magazine. Read the full feature here as they discuss everything from what drove Payton to found Numinus to what’s in store for the near future.  
December 8, 2021
1 2 3 36
Questions?
Call us toll-free 1-833-NUMINUS (686-4687)
crosschevron-down linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram